Bowel preparation for chronic kidney disease before colonoscopy
https://libcat.nshealth.ca/en/permalink/chpams35387
Nova Scotia Health Authority. Renal Program, Nova Scotia Health Authority. Pharmacy Services.
Halifax, NS:
Nova Scotia Health Authority
, 2020.
- Pamphlet Number
- 1475
- Available Online
- View Pamphlet
This pamphlet describes how to get ready for a colonoscopy if you have chronic kidney disease. Steps to prepare solutions on the day before your colonoscopy are listed. The day before your procedure and on the day of the test you should drink only clear liquids, and a suggested list is included. Remember not to eat any food or drink milk, or other liquids that are not clear, on the day before your colonoscopy or on the day of the test.
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Renal Program
- Nova Scotia Health Authority. Pharmacy Services
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2020
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document (5 p.) : digital, PDF file
- Subjects (MeSH)
- Cathartics
- Colonoscopy
- Renal Insufficiency, Chronic
- Subjects (LCSH)
- Laxatives
- Colonoscopy
- Chronic renal failure
- Specialty
- Medications
- Nephrology
- Abstract
- This pamphlet describes how to get ready for a colonoscopy if you have chronic kidney disease. Steps to prepare solutions on the day before your colonoscopy are listed. The day before your procedure and on the day of the test you should drink only clear liquids, and a suggested list is included. Remember not to eat any food or drink milk, or other liquids that are not clear, on the day before your colonoscopy or on the day of the test.
- Responsibility
- Prepared by: NSHA Renal Program Educators and Pharmacists
- Pamphlet Number
- 1475
Cinacalcet (Sensipar) for secondary hyperparathyroidism in chronic kidney disease (CKD)
https://libcat.nshealth.ca/en/permalink/chpams35371
Nova Scotia Health Authority. Renal Program.
Halifax, NS:
Nova Scotia Health Authority
, 2023.
- Pamphlet Number
- 1465
- Available Online
- View Pamphlet
Secondary hyperparathyroidism is a condition that can be caused by chronic kidney disease (CKD). It happens when your kidneys cannot filter out waste products the right way. This leads to too much parathyroid hormone in your blood. Cinacalcet (sin-a-KAL-cet) is a medication that lowers the amount of parathyroid hormone in your blood. This will help to balance the amount of calcium and phosphorous in your blood. Sensipar® is the brand name for cinacalcet. This pamphlet explains how to take cinac…
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Renal Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2023
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document ([4] p.) : digital, PDF file
- Subjects (MeSH)
- Cinacalcet
- Renal Insufficiency, Chronic - drug therapy
- Hyperparathyroidism, Secondary - drug therapy
- Subjects (LCSH)
- Chronic renal failure
- Hyperparathyroidism
- Kidneys--Diseases--Treatment
- Abstract
- Secondary hyperparathyroidism is a condition that can be caused by chronic kidney disease (CKD). It happens when your kidneys cannot filter out waste products the right way. This leads to too much parathyroid hormone in your blood. Cinacalcet (sin-a-KAL-cet) is a medication that lowers the amount of parathyroid hormone in your blood. This will help to balance the amount of calcium and phosphorous in your blood. Sensipar® is the brand name for cinacalcet. This pamphlet explains how to take cinacalcet, possible side effects, and how to store this medication.
- Notes
- Previous title: Sensipar (Cinacalcet) to treat secondary hyperparathyroidism in chronic kidney disease
- Previous title: Cinacalcet (Sensipar) to treat secondary hyperparathyroidism in chronic kidney disease (CKD)
- Responsibility
- Prepared by: Renal Program
- Pamphlet Number
- 1465
Erythropoieis-stimulating agents (ESAs) for chronic kidney disease (CKD) : with active cancer or a history of cancer or stroke
https://libcat.nshealth.ca/en/permalink/chpams37446
Nova Scotia Health Authority. Renal Program.
Halifax, NS:
Nova Scotia Health Authority
, 2021.
- Pamphlet Number
- 2217
- Available Online
- View Pamphlet
Erythropoiesis-stimulating agents (ESAs) are a group of medicines that help take the place of a hormone called erythropoietin (EPO). People with chronic kidney disease (CKD) may not have enough EPO coming from their kidneys to tell their body to make more red blood cells. This can cause their red blood cell count to drop and anemia (not enough red blood cells or hemoglobin in the blood) to develop. If you have CKD and active cancer or a history of cancer of stroke, it is important to carefully …
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Renal Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2021
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document ([2] p.) : digital, PDF file
- Subjects (MeSH)
- Renal insufficiency, chronic - complications
- Anemia - drug therapy
- Hematinics - therapeutic use
- Neoplasms
- Stroke
- Subjects (LCSH)
- Chronic renal failure--Complications
- Hematopoietic growth factors
- Renal anemia--Chemotherapy
- Cancer
- Cerebrovascular disease
- Abstract
- Erythropoiesis-stimulating agents (ESAs) are a group of medicines that help take the place of a hormone called erythropoietin (EPO). People with chronic kidney disease (CKD) may not have enough EPO coming from their kidneys to tell their body to make more red blood cells. This can cause their red blood cell count to drop and anemia (not enough red blood cells or hemoglobin in the blood) to develop. If you have CKD and active cancer or a history of cancer of stroke, it is important to carefully consider the risks and benefits of ESAs. The risks and benefits of ESAs are listed. Your health care team will talk with you about the risks and benefits of ESAs and other factors to consider when making the decision to take ESAs.
- Responsibility
- Prepared by: Renal Program
- Pamphlet Number
- 2217
Erythropoiesis-stimulating agent (ESA) therapy and chronic kidney disease (CKD)
https://libcat.nshealth.ca/en/permalink/chpams35406
Nova Scotia Health Authority. Renal Program.
Halifax, NS:
Nova Scotia Health Authority
, 2020.
- Pamphlet Number
- 1493
- Available Online
- View Pamphlet
Erythropoiesis-stimulating agents (ESAs) are a group of medicines that help take the place of a hormone called erythropoietin (EPO). People with chronic kidney disease (CKD) may not have enough EPO coming from their kidneys to tell their body to make more red blood cells. This can cause their red blood cell count to drop and anemia (not enough red blood cells or hemoglobin in the blood) to develop. How to take and store this medicine and possible side effects to watch for are reviewed.
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Renal Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2020
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document ([4] p.) : digital, PDF file
- Subjects (MeSH)
- Renal insufficiency, chronic - complications
- Anemia - drug therapy
- Hematinics - therapeutic use
- Subjects (LCSH)
- Chronic renal failure--Complications
- Hematopoietic growth factors
- Renal anemia--Chemotherapy
- Abstract
- Erythropoiesis-stimulating agents (ESAs) are a group of medicines that help take the place of a hormone called erythropoietin (EPO). People with chronic kidney disease (CKD) may not have enough EPO coming from their kidneys to tell their body to make more red blood cells. This can cause their red blood cell count to drop and anemia (not enough red blood cells or hemoglobin in the blood) to develop. How to take and store this medicine and possible side effects to watch for are reviewed.
- Responsibility
- Prepared by: Renal Program
- Pamphlet Number
- 1493
Fer injectable et insuffisance rénale chronique (IRC)
https://libcat.nshealth.ca/en/permalink/chpams37473
Nova Scotia Health Authority. Renal Program.
Halifax, NS:
Nova Scotia Health Authority
, 2020.
- Pamphlet Number
- 2161
- Available Online
- View Pamphlet
Si votre corps manque d’oxygène en raison d’une carence en fer, il se peut que vous soyez fatigué ou essoufflé. On appelle cela l’anémie ferriprive. Beaucoup de patients atteints d’insuffisance rénale chronique (IRC) ou dialysés souffrent d’anémie, car ils n’ont pas assez de globules rouges, et le corps a besoin de fer pour les fabriquer. Prendre du fer par injection permet donc au corps d’avoir suffisamment de fer pour fabriquer de l’hémoglobine, c’est-à-dire la protéine qui transporte l’oxygè…
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Renal Program
- Alternate Title
- Injectable iron and chronic kidney disease (CKD)
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2020
- Format
- Pamphlet
- Language
- French
- Physical Description
- 1 electronic document ([4] p.) : digital, PDF file
- Subjects (MeSH)
- Renal Dialysis
- Iron - therapeutic use
- Kidney Diseases
- Anemia, Iron-Deficiency
- Subjects (LCSH)
- Hemodialysis
- Chronic renal failure--Complications
- Iron deficiency anemia
- Abstract
- Si votre corps manque d’oxygène en raison d’une carence en fer, il se peut que vous soyez fatigué ou essoufflé. On appelle cela l’anémie ferriprive. Beaucoup de patients atteints d’insuffisance rénale chronique (IRC) ou dialysés souffrent d’anémie, car ils n’ont pas assez de globules rouges, et le corps a besoin de fer pour les fabriquer. Prendre du fer par injection permet donc au corps d’avoir suffisamment de fer pour fabriquer de l’hémoglobine, c’est-à-dire la protéine qui transporte l’oxygène. Ce dépliant explique comment prendre du fer injectable, ses effets possibles et comment le conserver.
- This pamphlet is a French translation of the English pamphlet 1495, "Injectable Iron and Chronic Kidney Disease (CKD)". If your body is not getting enough oxygen due to lack of iron, you may feel tired or short of breath. This is called iron deficiency anemia. Many patients with chronic kidney disease (CKD), or who are on dialysis, have anemia because their red blood cells are low. The body needs iron to help make new red blood cells. Getting iron injections can help make sure that you have enough iron in your body to make the oxygen-carrying part (hemoglobin) of your red blood cells. This pamphlet explains how to take injectable iron, side effects to watch for, and instructions on how to store the medication.
- Notes
- Previous title: Injectable iron sucrose and chronic kidney disease
- Responsibility
- Prepared by: NSHA Renal Program
- Pamphlet Number
- 2161
Injectable iron and chronic kidney disease (CKD)
https://libcat.nshealth.ca/en/permalink/chpams35408
Nova Scotia Health Authority. Renal Program.
Halifax, NS:
Nova Scotia Health Authority
, 2020.
- Pamphlet Number
- 1495
- Available Online
- View Pamphlet
If your body is not getting enough oxygen due to lack of iron, you may feel tired or short of breath. This is called iron deficiency anemia. Many patients with chronic kidney disease (CKD), or who are on dialysis, have anemia because their red blood cells are low. The body needs iron to help make new red blood cells. Getting iron injections can help make sure that you have enough iron in your body to make the oxygen-carrying part (hemoglobin) of your red blood cells. This pamphlet explains how …
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Renal Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2020
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document ([4] p.) : digital, PDF file
- Subjects (MeSH)
- Renal Dialysis
- Iron - therapeutic use
- Kidney Diseases
- Anemia, Iron-Deficiency
- Subjects (LCSH)
- Hemodialysis
- Chronic renal failure--Complications
- Iron deficiency anemia
- Abstract
- If your body is not getting enough oxygen due to lack of iron, you may feel tired or short of breath. This is called iron deficiency anemia. Many patients with chronic kidney disease (CKD), or who are on dialysis, have anemia because their red blood cells are low. The body needs iron to help make new red blood cells. Getting iron injections can help make sure that you have enough iron in your body to make the oxygen-carrying part (hemoglobin) of your red blood cells. This pamphlet explains how to take injectable iron, side effects to watch for, and instructions on how to store the medication. The French version of this pamphlet 2161, "Fer injectable et insuffisance rénale chronique (IRC)," is also available.
- Notes
- Previous title: Injectable iron sucrose and chronic kidney disease
- Responsibility
- Prepared by: NSHA Renal Program
- Pamphlet Number
- 1495
Lanthanum (Fosrenol) and chronic kidney disease (CKD)
https://libcat.nshealth.ca/en/permalink/chpams35370
Nova Scotia Health Authority. Renal Program.
Halifax, NS:
Nova Scotia Health Authority
, 2023.
- Pamphlet Number
- 1466
- Available Online
- View Pamphlet
Lanthanum (LAN-tha-num) is a medication used to lower the amount of phosphorus (a mineral that builds strong bones and teeth) in your blood. Lanthanum binds (attaches) to the phosphorus in the foods you eat and stops your body from taking it in. A person with chronic kidney disease (CKD) is less able to remove phosphorus from their body. When there is too much phosphorus in your blood, it pushes calcium out of your bones. This makes your bones weaker. Hemodialysis can remove some of the extra …
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Renal Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2023
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document ([4] p.) : digital, PDF file
- Subjects (MeSH)
- Renal Insufficiency, Chronic - drug therapy
- Renal Dialysis
- Lanthanum
- Subjects (LCSH)
- Chronic renal failure
- Kidneys--Diseases--Treatment
- Hemodialysis
- Abstract
- Lanthanum (LAN-tha-num) is a medication used to lower the amount of phosphorus (a mineral that builds strong bones and teeth) in your blood. Lanthanum binds (attaches) to the phosphorus in the foods you eat and stops your body from taking it in. A person with chronic kidney disease (CKD) is less able to remove phosphorus from their body. When there is too much phosphorus in your blood, it pushes calcium out of your bones. This makes your bones weaker. Hemodialysis can remove some of the extra phosphorus, but you may need a medication like lanthanam to remove more. Fosrenol® is the brand name for lanthanum. This pamphlet explains how to take lanthanum, possible side effects, and how to store this medication.
- Notes
- Previous title: Fosrenol (Lanthanum) and hemodialysis
- Responsibility
- Prepared by: Renal Program
- Pamphlet Number
- 1466
Management of chronic kidney disease : a clinician's guide
https://libcat.nshealth.ca/en/permalink/provcat33898
Mustafa Arici, editor.
--Heidelberg:
Springer
, c2014.
- Available Online
- View e-Book
- Location
- Online
This book presents a comprehensive and instructive management plan for physicians who care for CKD patients. Basic aspects of CKD, clinical assessment, evaluation and management of risk factors, cardiovascular disease in the context of CKD, assessment and management of CKD complications, special circumstances in CKD patients, and the path to renal replacement therapy are all thoroughly covered. Diagnostic and therapeutic approaches are presented according to the latest staging system for CKD, w…
- Available Online
- View e-Book
- Other Authors
- Arici, Mustafa
- Responsibility
- Mustafa Arici, editor
- Alternate Title
- Managing chronic kidney disease
- Place of Publication
- Heidelberg
- Publisher
- Springer
- Date of Publication
- c2014
- Physical Description
- 1 online resource (xvii, 513 pages)
- ISBN
- 9783642546372 (electronic bk.)
- 9783642546365
- Subjects (MeSH)
- Renal Insufficiency, Chronic - therapy
- Subjects (LCSH)
- Chronic renal failure - Treatment
- Abstract
- This book presents a comprehensive and instructive management plan for physicians who care for CKD patients. Basic aspects of CKD, clinical assessment, evaluation and management of risk factors, cardiovascular disease in the context of CKD, assessment and management of CKD complications, special circumstances in CKD patients, and the path to renal replacement therapy are all thoroughly covered. Diagnostic and therapeutic approaches are presented according to the latest staging system for CKD, with patient care being discussed separately for each disease stage. The proposed management plan is both 'best available evidence based' and 'practice based'. The book also recognizes the needs of busy clinicians by including helpful boxes summarizing the evidence on diagnostic and therapeutic issues and practice pearls based on guidelines.
- Contents
- CKD: Basics and Clinical Assessment -- CKD Risk Factors: Assessment and Management -- CKD and Cardiovascular Diseases -- CKD Complications: Assessment and Management -- CKD: Special Conditions -- CKD: Final Path to Renal Replacement Therapy.
- Format
- e-Book
- Location
- Online
One-Alpha® (alfacalcidol) and hemodialysis
https://libcat.nshealth.ca/en/permalink/chpams36672
Nova Scotia Health Authority. Pharmacy Services, Nova Scotia Health Authority. Renal Program.
Halifax, NS:
Nova Scotia Health Authority
, 2020.
- Pamphlet Number
- 1470
- Available Online
- View Pamphlet
One-Alpha® is a medicine that contains the active ingredient alfacalcidol, which is a form of vitamin D. The liver changes alfacalcidol to calcitriol, which is a form of vitamin D that can be used by the body. It acts as a hormone in your body to control the levels of calcium and phosphate, which are needed to build healthy bone. People with kidney disease cannot change enough vitamin D into calcitriol. We get vitamin D from sunlight, and from eating oily fish and milk products. This can cause …
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Pharmacy Services
- Nova Scotia Health Authority. Renal Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2020
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document ([4] p.) : digital, PDF file
- Subjects (MeSH)
- Renal Insufficiency, Chronic - drug therapy
- Renal Dialysis
- Subjects (LCSH)
- Chronic renal failure
- Kidneys--Diseases--Treatment
- Hemodialysis
- Abstract
- One-Alpha® is a medicine that contains the active ingredient alfacalcidol, which is a form of vitamin D. The liver changes alfacalcidol to calcitriol, which is a form of vitamin D that can be used by the body. It acts as a hormone in your body to control the levels of calcium and phosphate, which are needed to build healthy bone. People with kidney disease cannot change enough vitamin D into calcitriol. We get vitamin D from sunlight, and from eating oily fish and milk products. This can cause low levels of calcium in the blood and bone problems. This medicine skips the step done by the kidneys and increases the amount of vitamin D in your body that can be used. How to take the medicine and what side effects to watch for are reviewed. One-Alpha® is a brand name for alfacalcidol.
- Responsibility
- Prepared by: Renal Pharmacy Team, NSHA Renal Program
- Pamphlet Number
- 1470
Oral irons and chronic kidney disease (CKD)
https://libcat.nshealth.ca/en/permalink/chpams35375
Nova Scotia Health Authority. Renal Program.
Halifax, NS:
Nova Scotia Health Authority
, 2020.
- Pamphlet Number
- 1469
- Available Online
- View Pamphlet
Your red blood cells need iron to help carry oxygen through your body. Many people with chronic kidney disease (CKD) have anemia (not enough red blood cells or hemoglobin in the blood). Oral irons, such as ferrous sulfate, ferrous gluconate, ferrous fumarate, and FeraMAX® 150, will give you enough iron to make make hemoglobin. This will make sure your body gets enough oxygen. How to take and store these medicines, and what side effects to watch for are reviewed.
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Renal Program
- Alternate Title
- Oral irons and CKD
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2020
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document ([4] p.) : digital, PDF file
- Subjects (MeSH)
- Renal insufficiency, chronic - complications
- Renal Insufficiency, Chronic - drug therapy
- Anemia, Iron-Deficiency - drug therapy
- Abstract
- Your red blood cells need iron to help carry oxygen through your body. Many people with chronic kidney disease (CKD) have anemia (not enough red blood cells or hemoglobin in the blood). Oral irons, such as ferrous sulfate, ferrous gluconate, ferrous fumarate, and FeraMAX® 150, will give you enough iron to make make hemoglobin. This will make sure your body gets enough oxygen. How to take and store these medicines, and what side effects to watch for are reviewed.
- Responsibility
- Prepared by: Renal Program
- Pamphlet Number
- 1469
Over-the-counter medications and chronic kidney disease (CKD)
https://libcat.nshealth.ca/en/permalink/chpams35643
Nova Scotia Health Authority. Renal Program.
Halifax, NS:
Nova Scotia Health Authority
, 2023.
- Pamphlet Number
- 1636
- Available Online
- View Pamphlet
If you have chronic kidney disease (CKD), you need to know which over-the-counter medications are your best choices and which you should not take. This pamphlet lists over-the-counter medications you may need for a cough or cold, fever or pain, allergies, an upset stomach (indigestion, burning pain) or heartburn, nausea (feeling sick to your stomach) or vomiting (throwing up), diarrhea (loose, watery poop), and constipation, as well as multivitamins, and creams and ointments. Information on why…
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Renal Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2023
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document (9 p.) : digital, PDF file
- Subjects (MeSH)
- Nonprescription Drugs
- Renal Insufficiency, Chronic - drug therapy
- Subjects (LCSH)
- Drugs, Nonprescription
- Chronic renal failure
- Abstract
- If you have chronic kidney disease (CKD), you need to know which over-the-counter medications are your best choices and which you should not take. This pamphlet lists over-the-counter medications you may need for a cough or cold, fever or pain, allergies, an upset stomach (indigestion, burning pain) or heartburn, nausea (feeling sick to your stomach) or vomiting (throwing up), diarrhea (loose, watery poop), and constipation, as well as multivitamins, and creams and ointments. Information on why you should not take any herbal or natural health products is included.
- Notes
- Previous title: Over-the-counter medications & chronic kidney disease
- Responsibility
- Prepared by: Renal Program
- Pamphlet Number
- 1636
Rocaltrol® (calcitriol) and hemodialysis
https://libcat.nshealth.ca/en/permalink/chpams36671
Nova Scotia Health Authority. Pharmacy Services, Nova Scotia Health Authority. Renal Program.
Halifax, NS:
Nova Scotia Health Authority
, 2020.
- Pamphlet Number
- 1468
- Available Online
- View Pamphlet
Rocaltrol® is a medicine that contains the active ingredient calcitriol, which is a form of vitamin D that can be used by the body. It acts as a hormone in your body to control the levels of calcium and phosphate, which are needed to build healthy bone. People with kidney disease cannot change enough vitamin D into calcitriol. We get vitamin D from sunlight, and from eating oily fish and milk products. This can cause low levels of calcium in the blood and bone problems. This medicine skips the …
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Pharmacy Services
- Nova Scotia Health Authority. Renal Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2020
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document ([4] p.) : digital, PDF file
- Subjects (MeSH)
- Renal Insufficiency, Chronic - drug therapy
- Renal Dialysis
- Calcitriol
- Subjects (LCSH)
- Chronic renal failure
- Kidneys--Diseases--Treatment
- Hemodialysis
- Abstract
- Rocaltrol® is a medicine that contains the active ingredient calcitriol, which is a form of vitamin D that can be used by the body. It acts as a hormone in your body to control the levels of calcium and phosphate, which are needed to build healthy bone. People with kidney disease cannot change enough vitamin D into calcitriol. We get vitamin D from sunlight, and from eating oily fish and milk products. This can cause low levels of calcium in the blood and bone problems. This medicine skips the step done by the kidneys and increases the amount of vitamin D in your body that can be used. How to take the medicine and what side effects to watch for are reviewed. Rocaltrol® is a brand name for calcitriol.
- Responsibility
- Prepared by: Renal Pharmacy Team, NSHA Renal Program
- Pamphlet Number
- 1468
Sevelamer (Renagel) and chronic kidney disease (CKD)
https://libcat.nshealth.ca/en/permalink/chpams35372
Nova Scotia Health Authority. Renal Program.
Halifax, NS:
Nova Scotia Health Authority
, 2023.
- Pamphlet Number
- 1464
- Available Online
- View Pamphlet
Sevelamer (se-VEL-a-mer) is a medication that lowers the amount of phosphorus (a mineral that builds strong bones and teeth) in your blood. Sevelamer binds (attaches) to the phosphorus in the foods you eat and stops your body from taking it in. A person with chronic kidney disease (CKD) is less able to remove phosphorus from their body. When there is too much phosphorus in your blood, it pushes calcium out of your bones. This makes your bones weaker. Hemodialysis can remove some of the extra ph…
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Renal Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2023
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document ([4] p.) : digital, PDF file
- Subjects (MeSH)
- Sevelamer
- Renal Insufficiency, Chronic - drug therapy
- Renal Dialysis
- Subjects (LCSH)
- Hemodialysis
- Chronic renal failure
- Kidneys--Diseases--Treatment
- Abstract
- Sevelamer (se-VEL-a-mer) is a medication that lowers the amount of phosphorus (a mineral that builds strong bones and teeth) in your blood. Sevelamer binds (attaches) to the phosphorus in the foods you eat and stops your body from taking it in. A person with chronic kidney disease (CKD) is less able to remove phosphorus from their body. When there is too much phosphorus in your blood, it pushes calcium out of your bones. This makes your bones weaker. Hemodialysis can remove some of the extra phosphorus, but you may need a medication like sevelamer to remove more. Renagel® is one brand name for sevelamer. This pamphlet explains how to take sevelamer, possible side effects, and how to store this medication.
- Notes
- Previous title: Renagel (Sevelamer) and Hemodialysis
- Responsibility
- Prepared by: Renal Program
- Pamphlet Number
- 1464
Taking your medicines when you are sick: a guide for patients with chronic kidney disease (CKD)
https://libcat.nshealth.ca/en/permalink/chpams36519
Nova Scotia Health Authority. NSHA Renal Program.
Halifax, NS:
Nova Scotia Health Authority
, 2019.
- Pamphlet Number
- 1340
- Available Online
- View Pamphlet
This pamphlet lists medications to avoid when you are sick while managing chronic kidney disease. The pamphlet includes instructions for what to do if you are throwing up or have diarrhea, what to do if you are diabetic, as well as what to do if you are unsure whether to take a certain medication. It also gives a page for writing a sick day plan.
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. NSHA Renal Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2019
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document (5 p.) : digital, PDF file
- Subjects (LCSH)
- Chronic renal failure
- Kidneys--Diseases
- Abstract
- This pamphlet lists medications to avoid when you are sick while managing chronic kidney disease. The pamphlet includes instructions for what to do if you are throwing up or have diarrhea, what to do if you are diabetic, as well as what to do if you are unsure whether to take a certain medication. It also gives a page for writing a sick day plan.
- Notes
- Previous title: Taking your Medicines when you are Ill - A Guide for Patients with Chronic Kidney Disease
- Responsibility
- Prepared by: NSHA Renal Program
- Pamphlet Number
- 1340
